A recent randomized clinical trial evaluating odanacatib, a CTSK inhibitor developed for postmenopausal osteoporosis, has found that inhibition of the target lowered primary endpoints, but increased the risk of stroke (HR 1.32, P = 0.03) [42]. The gene discussed is CTSK; the disease is postmenopausal osteoporosis.